Communiqués Tvardi Therapeutics, Inc.

Actions

TVRD

US1407553072

Recherche biotechnologique et médicale

Cours en clôture Nasdaq 29/09/2026			Varia. 5j.	Varia. 1 janv.
1,280 ^USD	-3,76%		-18,47%	-70,23%

24/09	Tvardi Therapeutics, Inc. annonce la publication de données précliniques évaluant son inhibiteur de STAT3 dans la rectocolite hémorragique	CI
19/08	Transcript : Tvardi Therapeutics, Inc. - Special Call

Communiqués

24/09	New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)	AQ
26/08	Tvardi Therapeutics to Participate in Upcoming Investor Events	AQ
17/08	Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update	AQ
14/08	Tvardi: Q2 Earnings Snapshot	AQ
14/08	Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update	AQ
12/08	Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026	AQ
30/07	Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109	AQ
07/07	Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement	AQ
21/05	Tvardi Therapeutics to Participate in Upcoming Investor Events	AQ
08/05	Tvardi: Q1 Earnings Snapshot	AQ
08/05	Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update	AQ
02/04	Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium	AQ
31/03	Tvardi: Q4 Earnings Snapshot	AQ
31/03	Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update	AQ
12/02	Tvardi Therapeutics to Participate in Upcoming Investor Conferences	AQ
08/01	Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
08/01	Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights	AQ
28/12	INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics	NE
23/12	INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics	PR
18/12	TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics	NE
17/12	TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics	PR
16/12	TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics	NE
14/12	TVRD Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics	NE
11/12	TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics	PR
10/12	Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics	NE